Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electroporation-Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer
2020-004536-22Phase 2Terminated
- Sponsor
- Ole Thorlacius-Ussing
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Ole Thorlacius-Ussing. Primary endpoint: Objective response rate according to RECIST 1.1. Started Oct 2020; status: terminated.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2020-004536-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004536-22.